Dualitas Therapeutics secured $65 million in Series A funding to accelerate development of bispecific antibodies designed to engage two immune targets simultaneously. This approach, leveraging proximity biology, aims to provide superior efficacy over monoclonal antibodies for autoimmune and inflammatory conditions. Investors include Eli Lilly and Chugai Pharmaceutical, reflecting growing industry confidence in bispecific modalities. Dualitas’s platform offers promising avenues for immunomodulation and targeted therapy development.